| Paul Goldfinger, MD | |
|
113 Mount Hermon Way, Ocean Grove, NJ 07756-1411 | |
| (732) 988-4706 | |
| Not Available |
| Full Name | Paul Goldfinger |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 113 Mount Hermon Way, Ocean Grove, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871752196 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 098906-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Paul Goldfinger, MD 113 Mount Hermon Way, Ocean Grove, NJ 07756-1411 Ph: (732) 988-4706 | Paul Goldfinger, MD 113 Mount Hermon Way, Ocean Grove, NJ 07756-1411 Ph: (732) 988-4706 |
News Archive
A nationwide, government-sponsored study finds that people with a common form of diabetic retinopathy can benefit from a medication first developed to combat another potentially blinding disease, age-related macular degeneration (AMD). Treating diabetic macular edema (DME) with ranibizumab (Lucentis) eye injections, plus laser treatment if needed, appears to result in better vision than laser treatment alone, according to the Diabetic Retinopathy Clinical Research (DRCR) Network study published today in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy). DME is the main cause of vision loss in people with diabetes mellitus.
At a time when nearly 26 million Americans have diabetes and an estimated 79 million have pre-diabetes, JEWEL-OSCO, part of the nationwide SUPERVALU INC. family of grocery stores, is announcing its "Eating Healthy with my Diabetes" in-store tours for 2011.
Atherosclerosis is one of the commonest causes of death in modern societies. The condition is characterized by the build-up of fatty deposits called atherosclerotic plaques on the inner surfaces of arteries, which restrict, and may eventually cut off, blood flow. The deposits can also be dislodged from their site of origin and may then block major vessels in the heart or the brain, leading to life-threatening myocardial infarction or stroke.
ADM Tronics Unlimited, Inc. has announced that Angiodroid America, Inc. has withdrawn its Premarket Notification 510(k) application filed with the US Food and Drug Administration for Angiodroid The CO2 Injector for Angiography (the "Angiodroid Injector").
Chromosomal microarray (CMA)—a powerful test for diagnosing the genetic abnormalities causing some types of developmental delay and birth defects—can be used in an evidence-based manner to provide important information for patient treatment, according to a pair of studies in the September issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
› Verified 2 days ago
Dr. Young D Kong, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 97 Central Ave, Ocean Grove, NJ 07756 Phone: 732-774-4418 | |
Dr. Jeffrey M Beal, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 108 S Main St, Suite 6, Ocean Grove, NJ 07756 Phone: 732-776-8473 Fax: 732-869-9160 |